Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2018-10-31 Investor Presentation
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Roadshow New York
Investor Presentation Classification · 98% confidence The document is titled 'Roadshow New York' and dated '31 October 2018'. It contains detailed financial outlooks, guidance for FY/18, Q3/18 highlights, and strategic updates across various business segments (Fresenius Medical Care, Kabi, Helios, Vamed). The content structure, including slides, charts, and forward-looking statements, is characteristic of a presentation given to investors or analysts, often following an earnings announcement or as part of a strategic update tour. Since it is a presentation format detailing performance and outlook, it aligns best with an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it just a brief earnings release (ER); it is a comprehensive presentation deck.
2018-10-31 English
Q3 statement / Q3 financial report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Financial Report' for the Fresenius Group covering the 1st to 3rd quarters of 2018. It contains comprehensive financial statements, including consolidated statements of income, financial position, cash flows, and segment reporting, as well as a detailed management report. It is not an announcement of a report (RPA) or a simple regulatory filing (RNS), but the actual interim financial report itself. 9M 2018
2018-10-31 German
Telefonkonferenz Q3 2018, Fresenius
Call Transcript Classification · 99% confidence The document is explicitly titled "Conference Call – Q3/18 Results" and contains detailed financial tables for Q3/18 and Q1-3/18, segment performance reviews, and an updated FY/18 financial outlook. The structure, including highlights, current topics, and extensive P&L/Cash Flow tables, is characteristic of an earnings call presentation. Since it is a presentation summarizing period results, it is best classified as an Investor Presentation (IP). It is not the formal Earnings Release (ER) which is usually a press release with key figures, nor is it the full Quarterly Report (IR). The presence of the Q&A format implied by 'Conference Call' strongly suggests an Investor Presentation used during the call.
2018-10-30 English
Fresenius SE & Co. KGaA: Fresenius confirms and narrows Group guidance for FY 2018
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc' announcement dated October 16, 2018, disclosing an 'inside information' update regarding the company's guidance confirmation and narrowing for FY 2018. It discusses expected sales and net income growth based on preliminary Q3/18 performance. Crucially, it states: 'Fresenius will publish its detailed Q3/18 and Q1-Q3/18 financial results on October 30, 2018.' This indicates the document is an announcement about future financial reporting, not the detailed report itself. Since it is a formal, time-sensitive regulatory disclosure (indicated by 'Ad-hoc' and reference to MAR Regulation), but its primary function is to update guidance and announce the date of the full results, it fits best as an Earnings Release (ER) which often includes preliminary guidance updates, or potentially a Regulatory Filing (RNS) if it were less specific about earnings. Given the focus on confirming/narrowing guidance for the fiscal year based on recent performance, 'ER' (Earnings Release) is the most appropriate fit, as ERs frequently precede the full quarterly report (IR) by providing key highlights and outlook adjustments. It is not a full Interim Report (IR) because the detailed results are scheduled for a later date. FY 2018
2018-10-16 English
Roadshow South West USA
Investor Presentation Classification · 98% confidence The document is titled 'Roadshow USA' and contains extensive slides detailing company performance, segment breakdowns (Fresenius Medical Care, Kabi, Helios, Vamed), financial outlooks for FY/18, guidance tables, and a 'Financial Review Q2 & H1/18' section with P&L statements for Q2/18 and H1/18. This structure, focusing on presenting strategy, current performance, and future guidance to investors during a roadshow event, strongly indicates an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or an Earnings Release (ER) which typically only provides the initial summary announcement.
2018-10-02 English
Fresenius SE & Co. KGaA: Delaware court upholds Fresenius' termination of merger agreement with Akorn
Legal Proceedings Report Classification · 98% confidence The document is an 'Ad-hoc' announcement dated October 1, 2018, detailing a legal outcome regarding the termination of a merger agreement between Fresenius and Akorn. The content explicitly discusses a lawsuit, a court ruling (Delaware Court of Chancery), and the reasons for terminating a merger (breach of FDA data integrity requirements). This clearly falls under the category of reporting significant legal matters or regulatory actions involving the company. Based on the provided definitions, 'Legal Proceedings Report (LTR)' is the most appropriate classification, as it covers significant lawsuits and regulatory actions.
2018-10-01 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.